PHASE 1 TRIAL OF ENGINEERED ONCOLYTIC HSV-1 M032 IN NEWLY DIAGNOSED DIFFUSE MIDLINE GLIOMA

$1,354,543FY2025Defense Health AgencyDOD

The Univeristy Of Texas M.D. Anderson Cancer Center

Investigators